The problem is they don’t have a big pharma partner who is willing to inject upfront cash. So what would they say? They will simply dangle carrots and stretch as much as possible by building false expectations around Flaskworks as the trigger for big pharma investment or lure investors into believing that these new trials will be wrapped up in less than an year or two. Which is again BS. Even if they had decent funds available to deploy right away, they wont be able to finish a study in less than 3 years. With their funding situation and the way NWBO executes, expect another 5-6 years at the very least.
Or they will issue fluff PRs such as Oncovir partnership, which markets will simply dismiss it such as Roswell Park announcement. On the other hand, grant funding is not an answer to run large scale trials quickly and efficiently. It must be managed and funded by industry to get to the finish line (in terms of regulatory approvals).
Be prepared for another lost decade!
Market Data 
Markets 
AI
